Ovarian cancer blood test sends Vermillion shares skyrocketing. OXiGENE soars on leukemia trial start. Q1 profit sends Sunesis shares higher. Print E-mail
By BioMedReports.com Staff   
Thursday, 12 May 2011 20:41
Below is a look at some of the headlines for companies that made news in the healthcare sector on May 12, 2011.

Shares of Vermillion, Inc. (Nasdaq:VRML), jumped 73% today after a study published online ahead of print in the June 2011 edition of Obstetrics & Gynecology demonstrated that American College of Obstetrics and Gynecology (ACOG) guidelines for determining the likelihood that an ovarian mass is cancerous prior to surgery would accurately identify more women with ovarian cancer if the OVA1 blood test were used in place of the currently recommended CA 125 blood test. The study builds on prior research that shows accurate assessment of an ovarian mass for cancer prior to surgery can affect both treatment decisions and health outcomes for women with ovarian cancer.

OVA1 is the first test cleared by the U.S. Food and Drug Administration (FDA) for aiding in the pre-surgical evaluation of a woman's ovarian mass for cancer. Vermillion developed OVA1, and Quest Diagnostics Incorporated (NYSE:DGX), the world's leading diagnostic testing company, offers OVA1 testing services in the United States and India. Quest Diagnostics and Vermillion both participated in the study and Vermillion also helped fund the study. Neither company had any involvement in the development of the manuscript.
 
Shares of Vermillion gained $2.46 to $5.83. After the bell, shares were up another 69 cents or 12% to $6.51.
 
Shares of OXiGENE, Inc. (Nasdaq:OXGN), soared today after the company announced that investigators at the University of Florida have initiated an investigator sponsored Phase 1 study of OXi4503 for the treatment of patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS). OXi4503 is a novel, next-generation anticancer agent that is the first compound to combine vascular disrupting activity with direct cytotoxicity, the latter mediated through a reactive quinone metabolite. The open-label, dose-escalating study, which is sponsored in part by The Leukemia & Lymphoma Society's Therapy Acceleration Program, will be conducted in patients with relapsed or refractory AML or MDS and will evaluate the safety profile, maximum tolerated dose (MTD) and biologic activity of OXi4503.
 
"Based on the positive data from earlier preclinical studies of OXi4503, we believe this trial could represent an important step in advancing a new therapeutic option for patients with AML and MDS, especially older adults, who have failed to respond or have relapsed on other therapies," said Christopher R. Cogle, M.D., of the University of Florida and lead investigator of the study.
 
Shares of OXiGENE traded as high as $6.07, before pulling back and settling the day at $5.60, up 70 cents or 14.29%.

Shares of Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) jumped higher today after the company reported financial results for the quarter ended March 31, 2011. The company reported net income of $1.8 million, or 4 cents per share, for the three months ended March 31. That compares with a net loss of $4.6 million, or 65 cents per share, for the same period a year ago.
 
In April, Millennium Pharmaceuticals paid Sunesis $4 million, the companies will team up to study experimental treatments for cancer. Sunesis could receive another $60 million in milestone payments and royalties on sales.
 
Shares of Sunesis jumped 35 cents or 14% to $2.87.


Also Thursday:


AcelRx Pharmaceuticals, Inc. (Nasdaq:ACRX)
, ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, reported financial results today for the first quarter ended March 31, 2011.

AdCare Health Systems, Inc. (NYSE Amex: ADK), a leading skilled nursing and assisted living provider, has been invited to present at 'SEVEN,' Noble Financial Capital Markets' Seventh Annual Equity Conference.

Adia Nutrition, a subsidiary of 3Me, Inc. (PINKSHEETS: PIVX), is proud and to announce the launch of its chewable probiotic on May 21, 2011 at Earthfest in Boston.

Bacterin International Holdings, Inc. (NYSE Amex:BONE) ("Bacterin"), a creator and developer of revolutionary bone graft material and anti-microbial coatings for medical applications, today reported financial results for its first quarter ended March 31, 2011.

Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), has been named one of the "2011 Best Places to Work in the Bay Area" by the San Francisco Business Times.

Callidus Software Inc. (NASDAQ: CALD), the leader in Sales Performance Management (SPM), announced today that Saint Mary's Health Plans, a Nevada based health insurer, has selected Callidus Software's ActekSoft ACom3 Commission and Incentive Compensation System.

China Biologic Products, Inc. (Nasdaq:CBPO)
("China Biologic," or the "Company"), a leading plasma-based biopharmaceutical company in China, today announced that it will present at two investor conferences in New York City in May 2011.

Cord Blood America, Inc. (OTC BB: CBAID), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, announced today that it is reducing the monthly payment in its unique "Afford-A-Cord" storage program from $29 a month to $19.

Cornerstone Therapeutics Inc. (NASDAQ: CRTX) today reported total net revenues of $30.0 million for the first quarter of 2011, compared to $36.4 million reported for the first quarter last year.

General Cannabis, Inc. (PINKSHEETS: CANA) today announced that its wholly owned subsidiary, WeedMaps Media, Inc., reported increased revenue for the 17th consecutive month and also reported positive trends at its subsidiary, General Merchant Solutions, Inc.

InspireMD, Inc. (OTC BB: NSPR) ("Inspire" or the "Company"), the developer of the MGuard™ mesh protective stent system, is happy to announce that MGuard is now available in India.

mPhase Technologies, Inc. (OTCBB: XDSL) today released a photograph that shows its smart surface technology's dramatic ability to repel liquids. In the embedded photograph the viewer can see individual water droplets in a 3x4 array sitting on top of an mPhase created smart porous silicon membrane.

NHS Health Solutions, Incorporated (PINKSHEETS: NHSH), a Nevada corporation, announced today, May 12, 2011, that NHS Health Solutions, Inc. completed a merger with Centacom Corporation and its subsidiaries ("Centacom" or "Company"), headquartered in Jacksonville, Florida.

Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the quarter ended March 31, 2011.

PacificHealth Laboratories, Inc. (OTCQB: PHLI), a nutrition technology company, announced today that they have completed a private placement of its common stock resulting in net proceeds to the Company of $620,000.

Palatin Technologies, Inc. (NYSE Amex:PTN) will host a conference call and webcast on May 16, 2011 at 11:00 a.m. Eastern Time to discuss its quarter ended March 31, 2011 financial results and its programs, focusing on the upcoming start of its Phase 2 clinical trial with bremelanotide for women with female sexual dysfunction.

Protalix BioTherapeutics, Inc. (NYSE-AMEX:PLX, TASE:PLX), today announced that members of the Company's senior management will present the Company's corporate presentation at four upcoming life science conferences.

Savanna East Africa, Inc. (PINKSHEETS: NVAE) recently announced the Company has scheduled an update Webcast from CEO Randell Torno for release next Tuesday, May 17th.

SeraCare Life Sciences, Inc. (NASDAQ:SRLS), a global life sciences company providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics, today reported operational and financial results for its second quarter of fiscal year 2011, ended March 31, 2011.

Siemens Healthcare (NYSE:SI)
has appointed Gregory Sorensen, MD, as chief executive officer (CEO) of Siemens Healthcare in the U.S.A., effective June 1.

Techs Loanstar, Inc. (OTCQB: TCLN) (PINKSHEETS: TCLN)
today announced additional details in its plans to acquire Q'uture Inc. ("Q'uture").

Tengion, Inc. (Nasdaq:TNGN) today provided a business update and reported its financial results for the three months ended March 31, 2011.

Varian Medical Systems, Inc. (NYSE:VAR), the world's leading supplier of medical technology for treating cancer with radiotherapy, and privately-held Augmenix, Inc. today announced that they have reached an agreement under which Varian will make a $15 million minority equity investment in Augmenix, a company that is developing hydrogel products to improve outcomes in radiation oncology.  

Verenium Corporation (Nasdaq:VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today reported a summary of recent Company highlights and financial results for the first quarter ended March 31, 2011.

VentriPoint Diagnostics Ltd. (TSX VENTURE:VPT) (PINK SHEETS:VPTDF) as part if its controlled rollout strategy, is announcing a new VMS™ research site for right heart analysis in the United States at Riley Hospital for Children at Indiana University Health System.

VisualMED Clinical Solutions Corp. (PINKSHEETS: VMCS) (FRANKFURT: VA6.F) announces that it will proceed with the implementation of its signature smart electronic health record with full CPOE, decision support and medical alerts at a private general practice facility in southern Florida.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter